Introduction {#section5-1753466619866096}
============

Chronic obstructive pulmonary disease (COPD) kills more than 3 million people worldwide every year.^[@bibr1-1753466619866096]^ Many factors have been reported to be associated with COPD, including systemic and local inflammation, air pollution and a sedentary lifestyle.^[@bibr2-1753466619866096][@bibr3-1753466619866096]--[@bibr4-1753466619866096]^ However, the exact mechanisms underlying COPD still remain unclear. Since COPD is a chronic inflammatory disease, the relationship between inflammation and COPD has been widely evaluated. Tumor necrosis factor-α (TNF-α), one of the major inflammatory factors, is implicated in the pathogenesis of many disorders, including COPD.^[@bibr5-1753466619866096],[@bibr6-1753466619866096]^ However, due to the small sample sizes, most studies lack adequate statistical power to clarify the relationship between TNF-α and COPD. Moreover, currently available studies have provided inconsistent, or even contrary, results. For example, Karadag and colleagues have pointed out that raised serum level of TNF-α can be used as a biomarker for the systemic inflammatory response in stable COPD patients.^[@bibr7-1753466619866096]^ But Franciosi and colleagues showed that healthy people and COPD patients at different stages had no statistical difference in TNF-α concentrations.^[@bibr8-1753466619866096]^ To comprehensively investigate the association between TNF-α and COPD, and evaluate the diagnostic value of TNF-α in COPD, we conducted this meta-analysis to systematically evaluate the relationship between them.

Materials and methods {#section6-1753466619866096}
=====================

Literature search {#section7-1753466619866096}
-----------------

We systematically searched four electronic databases (PubMed, Web of Science, EMBASE, and Cochrane library database CENTRAL) up to May 2018. The search terms were \['pulmonary disease, chronic obstructive' (MeSH Terms) or 'chronic obstructive pulmonary disease' or 'COPD' or 'COAD' or 'chronic obstructive airway disease' or 'chronic obstructive lung disease' or 'emphysema' or 'chronic bronchitis'\] and \['Tumor necrosis factor-a' (MeSH Terms) or 'Tumor necrosis factor-a 'or 'TNF-α'\] and ('systemic inflammation' or 'biological markers') ([Supplementary Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1753466619866096)). Only articles published in English were included. We also went through the references of eligible studies and review articles manually to identify possible relevant publications.

Study selection and inclusion and exclusion criteria {#section8-1753466619866096}
----------------------------------------------------

The inclusion criteria, set according to the PICOS framework (population, intervention, comparison, outcomes, study design), were as follows ([Table 1](#table1-1753466619866096){ref-type="table"}): population, COPD patients; intervention, TNF-α; comparison, healthy control or non-COPD; outcomes, concentration of TNF-α; study design, case-control study.

###### 

PICOS table of included studies.

![](10.1177_1753466619866096-table1)

  Category       Description                   Search strategy terms
  -------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Population     COPD                          COPD OR Chronic obstructive pulmonary disease
  Intervention   TNF-α                         TNF-α OR Tumor necrosis factor-alpha
  Control        Healthy control or non-COPD   Healthy control or non-COPD
  Outcome        Concentration of TNF-α        TNF-α concentration OR TNF-α level
  Study Design   Case-control study            Case-Control study OR Case-Comparison Studies OR Case-compare study OR case-referent study OR Matched case-control study NOT animals

COPD, chronic obstructive pulmonary disease; PICOS, population, intervention, comparison, outcomes, study design; TNF-α, tumor necrosis factor-alpha

The eligible studies had to meet all of the following criteria: evaluation of the association between TNF-α and COPD was described; the specific concentration of TNF-α was provided; TNF-α level in both the control and COPD group was provided; sufficient patient data for calculating standard mean difference (SMD) and its 95% confidence intervals (CIs) were provided; COPD patients were diagnosed according to the criteria of the American Thoracic Society or Global Initiative for Chronic Obstructive Lung Disease; and healthy controls who had no medical illness or abnormalities in physical examination and laboratory date, and presented no symptoms of infection, were included. The exclusion criteria included: patients who received nutritional support with therapy; conference papers, reports, comments or review articles; studies without a control group; and patients with a history or diagnosis of asthma, allergy, or respiratory diseases other than COPD. The reasons for exclusion are shown in [Table 2](#table2-1753466619866096){ref-type="table"}.

###### 

Exclusion criteria.

![](10.1177_1753466619866096-table2)

  Characteristics of excluded studies                                                                Reasons
  -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients who received nutritional support with therapy                                             Nutritional support is likely to affect the expression of TNF-α
  Conference papers, reports, comments or review articles                                            Conference papers, reports, comments, or review articles do not have enough case-control studies. These paper cannot provide enough data about PICOS
  Without control group                                                                              All included studies are case-control studies, in which patients with COPD are diagnosed as cases, and individuals who do not have the disease or non-COPD are comparable as controls
  Patients with a history or diagnosis of asthma, allergy, or respiratory diseases other than COPD   The aim of this review was to investigate the relationship between TNF-α and COPD rather than other respiratory diseases

COPD, chronic obstructive pulmonary disease; TNF-α, tumor necrosis factor-alpha

Quality assessment {#section9-1753466619866096}
------------------

Two reviewers (YY and ZJ) independently evaluated the quality of included studies according to the Newcastle-Ottawa Quality Assessment Scale (NOS). The NOS is a semiquantitative scale composed of three domains: selection, comparability, and exposure. The maximum NOS score is 9: a study with a total score of ⩽3 was considered as poor quality, those scoring 4--6 were of moderate quality, and a score of 7--9 was considered high quality.

Data extraction {#section10-1753466619866096}
---------------

Two investigators (DX and YY) independently extracted the following information from the original studies: first author's name, year of publication, country, sample size, clinical characteristics \[including sex ratio, mean ages, smoking status, COPD status, body mass index (BMI), and the predicted first second of forced expiration (FEV~1~)\]. Disagreements between the two reviewers were resolved by consultation with a third reviewer (WSY).

Statistical analysis {#section11-1753466619866096}
--------------------

The RevMan 5.3 software was used to perform the meta-analysis. The SMD and corresponding 95% CI were calculated to evaluate the relationships between TNF-α level and COPD. The Chi-squared test and *I*^2^ statistics were applied to detect the heterogeneity among studies. A *p* \< 0.05 in Chi-squared test or *I*^2^ \> 50% indicated the presence of significant heterogeneity. A random effect model or fixed model was then used based on the presence or absence of significant heterogeneity. A sensitivity analysis was performed to explore the origins of heterogeneity. Publication bias was assessed using funnel plots with standard error.

Results {#section12-1753466619866096}
=======

Study selection {#section13-1753466619866096}
---------------

The initial literature search returned a total of 949 articles. We excluded 143 duplicated studies. After a careful review of the titles and abstracts of remaining studies, a further 433 articles were excluded, and another 323 articles were also excluded for various reasons. Finally, 40 studies involving 4189 COPD patients and 1676 healthy controls were included in this meta-analysis.^[@bibr9-1753466619866096][@bibr10-1753466619866096][@bibr11-1753466619866096][@bibr12-1753466619866096][@bibr13-1753466619866096][@bibr14-1753466619866096][@bibr15-1753466619866096][@bibr16-1753466619866096][@bibr17-1753466619866096][@bibr18-1753466619866096][@bibr19-1753466619866096][@bibr20-1753466619866096][@bibr21-1753466619866096][@bibr22-1753466619866096][@bibr23-1753466619866096][@bibr24-1753466619866096][@bibr25-1753466619866096][@bibr26-1753466619866096][@bibr27-1753466619866096][@bibr28-1753466619866096][@bibr29-1753466619866096][@bibr30-1753466619866096][@bibr31-1753466619866096][@bibr32-1753466619866096][@bibr33-1753466619866096][@bibr34-1753466619866096][@bibr35-1753466619866096][@bibr36-1753466619866096][@bibr37-1753466619866096][@bibr38-1753466619866096][@bibr39-1753466619866096][@bibr40-1753466619866096][@bibr41-1753466619866096][@bibr42-1753466619866096][@bibr43-1753466619866096][@bibr44-1753466619866096]--[@bibr45-1753466619866096]^ The flowchart for the literature search is presented in [Figure 1](#fig1-1753466619866096){ref-type="fig"}.

![Flow diagram of the literature search process.](10.1177_1753466619866096-fig1){#fig1-1753466619866096}

The characteristics of the included studies are summarized in [Table 3](#table3-1753466619866096){ref-type="table"}. Eight studies had a NOS score of 9^[@bibr25-1753466619866096],[@bibr29-1753466619866096],[@bibr33-1753466619866096],[@bibr36-1753466619866096],[@bibr37-1753466619866096],[@bibr40-1753466619866096],[@bibr42-1753466619866096],[@bibr45-1753466619866096]^; seven studies scored 8^[@bibr13-1753466619866096][@bibr14-1753466619866096]--[@bibr15-1753466619866096],[@bibr17-1753466619866096],[@bibr18-1753466619866096],[@bibr22-1753466619866096],[@bibr44-1753466619866096]^; nine studies scored 7^[@bibr11-1753466619866096],[@bibr19-1753466619866096],[@bibr30-1753466619866096],[@bibr31-1753466619866096],[@bibr34-1753466619866096],[@bibr35-1753466619866096],[@bibr38-1753466619866096],[@bibr41-1753466619866096],[@bibr46-1753466619866096]^; ten studies scored 6^[@bibr9-1753466619866096],[@bibr10-1753466619866096],[@bibr12-1753466619866096],[@bibr24-1753466619866096],[@bibr27-1753466619866096],[@bibr28-1753466619866096],[@bibr32-1753466619866096],[@bibr43-1753466619866096],[@bibr47-1753466619866096],[@bibr48-1753466619866096]^; four studies scored 5^[@bibr16-1753466619866096],[@bibr20-1753466619866096],[@bibr26-1753466619866096],[@bibr39-1753466619866096]^; and the last two studies scored 4.^[@bibr21-1753466619866096],[@bibr23-1753466619866096]^ The NOS scores suggested that all included studies were of moderate or high quality. Regarding location, the majority of studies were from Europe,^[@bibr26-1753466619866096]^ two studies were from the US,^[@bibr14-1753466619866096],[@bibr26-1753466619866096]^ one study was from Africa,^[@bibr15-1753466619866096]^ and eight studies were from Asia.^[@bibr22-1753466619866096],[@bibr29-1753466619866096],[@bibr32-1753466619866096],[@bibr34-1753466619866096],[@bibr35-1753466619866096],[@bibr38-1753466619866096],[@bibr43-1753466619866096],[@bibr45-1753466619866096]^ Patients in 9 studies were treated with steroids, while patients in the remaining 24 studies were not treated with steroids. The mean age, smoking status, COPD status, gender, and BMI of the study participants in the included studies are also provided in [Table 3](#table3-1753466619866096){ref-type="table"}.

###### 

Characteristics of the included studies.

![](10.1177_1753466619866096-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Year   Country       Sample size   Mean age        Sex(male/Female)   Smoking\    Reversibility\   Treat with        COPD\    NOS                      
                                                                                                                      status      test                               status                            
  --------------------------------------------- ------ ------------- ------------- --------------- ------------------ ----------- ---------------- ----------------- -------- --------- -------------- ---
  Calikoglu^[@bibr9-1753466619866096]^          2004   Turkey        41            62.18 ± 2.50    54.73 ± 2.23       NR          NR               NR                No       NR        Exacerbated    6

  Agusti^[@bibr10-1753466619866096]^            2012   Spain         2409          63.5 ± 7.1      53.0 ± 8.6         1160/1004   76/169           NR                Yes      NR        NR             6

  Once^[@bibr11-1753466619866096]^              2010   Turkey        73            62.8 ± 5.5      61.8 ± 7.4         38/2        31/2             Ex-smokers        No       No        NR             7

  Kleniewska^[@bibr12-1753466619866096]^        2016   Poland        42            59.8 ± 6.7      43.7 ± 14.4        20/0        15/7             NR                Yes      No        Stable         6

  Rovina^[@bibr13-1753466619866096]^            2007   Greece        30            54 ± 9          46 ± 11            NR          NR               Current-smokers   Yes      No        NR             8

  Gagnon^[@bibr14-1753466619866096]^            2014   Canada        56            65 ± 6          62 ± 8             25/12       13/6             Ex-smokers        No       NR        Mild           8

  Ben Anes^[@bibr15-1753466619866096]^          2017   Tunisia       285           61.58 ± 1.75    58.15 ± 0.7        50/6        203/26           Ex-smokers        Yes      NR        Exacerbated    8

  Perez-deLiano^[@bibr16-1753466619866096]^     2017   Spain         109           65.6 ± 10.1     59.8 ± 10.5        18/26       53/12            NR                Yes      NR        NR             5

  FoschinoBarbaro^[@bibr17-1753466619866096]^   2007   UK            42            NR              NR                 24/3        12/3             Ex-smokers        Yes      No        Stable         8

  Barreiro^[@bibr18-1753466619866096]^          2013   Spain         21            59 ± 8          58 ± 14            9           12               Ex-smokers        No       No        NR             8

  Beeh^[@bibr19-1753466619866096]^              2003   Germany       26            59 ± 9.25       31 ± 8.75          8/4         8/6              Ex-smokers        Yes      No        Stable         7

  Di Stefano^[@bibr20-1753466619866096]^        2018   Italy         41            NR              NR                 19/4        8/10             Ex-smokers        Yes      No        Exacerbated    5

  Breyer^[@bibr21-1753466619866096]^            2011   Netherlands   127           NR              NR                 NR          NR               Ex-smokers        No       No        Exacerbated    4

  Zhang^[@bibr22-1753466619866096]^             2016   China         89            61.14 ± 10.21   60.92 ± 9.62       30/20       23/16            NR                Yes      No        Moderate       8

  Dima^[@bibr23-1753466619866096]^              2010   Greece        38            58.4 ± 2.0      41.5 ± 3.5         NR          NR               Ex-smokers        Yes      No        NR             4

  Kawayama^[@bibr24-1753466619866096]^          2016   UK            20            62.2 ± 6.6      64.2 ± 6.6         7/3         5/5              Ex-smokers        No       Inhaled   NR             6

  Gaki^[@bibr25-1753466619866096]^              2011   Greece        354           63 ± 1.86       60 ± 1.71          169/53      97/35            Ex-smokers        No       Inhaled   Stable         9

  Godoy^[@bibr26-1753466619866096]^             2003   Brazi         24            62 ± 2.25       54 ± 1.5           14/0        5/5              NR                No       No        NR             5

  Hacievliyagil^[@bibr27-1753466619866096]^     2012   Turkey        40            61.2 ± 1.7      59.1 ± 5.4         17/3        14/6             NR                Yes      Oral      Stable         6

  Huertas^[@bibr28-1753466619866096]^           2010   Italy         33            69 ± 8          63 ± 7             NR          NR               NR                No       No        Stable         6

  Ju^[@bibr29-1753466619866096]^                2011   China         130           65.17 ± 6.79    63.98 ± 5.77       54/16       21/39            Ex-smokers        Yes      No        Stable         9

  Karadag^[@bibr30-1753466619866096]^           2007   Turkey        125           63.5 ± 7.59     61.10 ± 7.68       NR          NR               NR                Yes      Inhaled   Stable         7

  Karadag^[@bibr31-1753466619866096]^           2008   Turkey        65            65.6 ± 7.8      63.2 ± 7.6         NR          NR               Ex-smokers        Yes      No        Stable         7

  Shin^[@bibr32-1753466619866096]^              2007   Korea         105           63.6 ± 7.4      66.5 ± 8.9         NR          NR               NR                No       No        Stable         6

  Kythreotis^[@bibr33-1753466619866096]^        2008   Greece        77            65.8 ± 8.3      65.9 ± 9.6         43/9        19/6             Ex-smokers        No       No        Exacerbation   9

  Liu^[@bibr34-1753466619866096]^               2009   China         63            70 ± 7          70 ± 7             NR          NR               No-smoker         No       No        Stable         7

  Huang^[@bibr35-1753466619866096]^             2016   China         67            60.2 ± 10.1     55.7 ± 10.3        21/11       19/16            NR                Yes      NR        NR             7

  Moermans^[@bibr36-1753466619866096]^          2011   Belgium       128           62 ± 12         40 ± 12            73/21       24/10            Ex-smokers        Yes      Yes       Stable         9

  Piehl-Aulin^[@bibr37-1753466619866096]^       2008   Sweden        40            64 ± 8.7        61.9 ± 7.9         11/15       7/7              Ex-smokers        No                 Stable         9

  Tan^[@bibr38-1753466619866096]^               2016   China         20            65 ± 3          50 ± 5             6/4         4/6              Ex-smokers        Yes      Yes       Stable         7

  Guiot^[@bibr39-1753466619866096]^             2017   Belgium       62            63 ± 9          55 ± 9             24/8        11/19            NR                No       NR        NR             5

  Sarioglu^[@bibr40-1753466619866096]^          2015   Turkey        175           64.0 ± 8.9      61.5 ± 9.2         100/10      55/10            Ex-smokers        Yes      No        Stable         9

  Uzum ^[@bibr41-1753466619866096]^             2013   Turkey        49            65.9 ± 10.0     50.2 ± 8.4         NR          NR               No-smoker         No       No        Stable         7

  Kosacka^[@bibr42-1753466619866096]^           2015   Poland        210           62.2 ± 9.37     49.48 ± 13.68      121/60      18/11            Ex-smokers        No       NR        Stable         9

  Cheng^[@bibr43-1753466619866096]^             2008   China         343           71.9 ± 8.0      74.7 ± 3.7         152/32      129/30           Ex-smokers        Yes      NR        NR             6

  Valipour^[@bibr44-1753466619866096]^          2008   Austria       60            62 ± 9          59 ± 8             23/7        23/7             NR                Yes      No        Exacerbation   8

  Zhang^[@bibr45-1753466619866096]^             2010   China         65            70.93 ± 5.58    69.16 ± 7.43       38/8        13/6             Ex-smokers        Yes      No        Stable         9

  Soler^[@bibr46-1753466619866096]^             1999   Spain         21            68 ± 9          51 ± 11            13/0        5/3              Ex-smokers        No       No        Stable         7

  Vera^[@bibr47-1753466619866096]^              1996   UK            30            62.5 ± 3.2      39.4 ± 3.1         NR          NR               Ex-smokers        No       No        NR             6

  De Godoy^[@bibr48-1753466619866096]^          1996   US            23            67.0 ± 4.9      63.5 ± 5.8         6/4         11/2             NR                No       No        NR             6
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; NOS, Newcastle-Ottawa Quality Assessment Scale; NR, not recorded

Meta-analysis {#section14-1753466619866096}
-------------

Due to the existence of significant heterogeneity (*p* \< 0.00001, *I*^2^ = 98%), this meta-analysis used a random effect model. Compared with the control group, the COPD patients had a significantly elevated level of TNF-α (SMD: 1.45, 95% CI: 0.44--2.27, *p* \< 0.00001) ([Figure 2](#fig2-1753466619866096){ref-type="fig"}).

![Comparison of tumor necrosis factor-α level between COPD patients and controls in the included studies.\
CI, Confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.](10.1177_1753466619866096-fig2){#fig2-1753466619866096}

Subgroup analysis {#section15-1753466619866096}
-----------------

Subsequently, subgroup analyses stratified for FEV~1~%, smoking history, COPD status, country, mean age, and BMI were performed to further understand the association between TNF-α level and COPD, and discover the source of heterogeneity ([Table 4](#table4-1753466619866096){ref-type="table"}). A total of 36 studies were included in the subgroup analysis based on FEV~1~%; the TNF-α level was 1.49 higher in COPD group compared with the control group (95% CI: 0.89--2.00, *p* \< 0.00001) ([Figure 3](#fig3-1753466619866096){ref-type="fig"}). The heterogeneity was still significant (\>50%: *p* \< 0.00001, *I*^2^ = 94%; \<50%: *p* \< 0.0001, *I*^2^ = 98%). In the subgroup analysis based on smoking status ([Figure 4](#fig4-1753466619866096){ref-type="fig"}), the TNF-α level in the ex-smokers/current smoker group was higher than those in the control and case groups (SMD: 1.63, 95% CI: 0.77--2.49, *p* = 0.0002), but was not different for smoking patients (SMD: 0.70, 95% CI: --1.36 to 2.76, *p* = 0.51). The heterogeneity in both groups was still significant (ex-smokers/current smoker: *p* \< 0.00001, *I*^2^ = 98%; No: *p* \< 0.00001, *I*^2^ = 95%). A subgroup analysis was then performed according to COPD status ([Figure 5](#fig5-1753466619866096){ref-type="fig"}). Patients with stable COPD and exacerbated COPD had higher TNF-α levels than the control group (stable: SMD: 1.33, 95% CI: 0.46--2.21, *p* = 0.003; exacerbated: SMD: 2.43, 95% CI: 0.29--4.57, *p* = 0.03), but the heterogeneity was still significant regardless of COPD status (stable: *p* \< 0.00001, *I*^2^ = 98%; exacerbated: *p* \< 0.00001, *I*^2^ = 99%). Moreover, a subgroup analysis was carried out based on mean age ([Figure 6](#fig6-1753466619866096){ref-type="fig"}). The TNF-α level in age \>60 groups was 0.98 higher than that of the control group (SMD: 0.98 95% CI: 0.29--1.68, *p* = 0.006). The heterogeneity was still significant in both groups (\>60: *p* \< 0.00001, *I*^2^ = 97%; \<60: *p* \< 0.00001, *I*^2^ = 91%) ([Figure 6](#fig6-1753466619866096){ref-type="fig"}). In addition, in the country and BMI subgroup, the TNF-α level in the case group was significantly higher than that of the control group (Europe: SMD: 1.58, 95% CI: 0.94--2.23, *p* \< 0.00001; others: SMD: 1.76, 95% CI: 0.78--2.74, *p* = 0.0004) (BMI ⩾20: SMD: 8.53, 95% CI: 7.43--9.62, *p* \< 0.00001; BMI \<20: SMD: 4.85, 95% CI: --3.22 to 12.93, *p* = 0.24). The heterogeneity was still obvious (Europe: *p* \< 0.00001, *I*^2^ = 98%; others: *p* \< 0.00001, *I*^2^ = 98%) (BMI ⩾ 20: *p* \< 0.00001, *I*^2^ = 100%; BMI \< 20: *p* \< 0.00001, *I*^2^ = 95%). ([Figures 7](#fig7-1753466619866096){ref-type="fig"} and [8](#fig8-1753466619866096){ref-type="fig"}). Finally, subgroup analysis was performed based on sample source. The TNF-α level in the case group was significantly higher than that of the control group in serum and BAL; the difference has statistical significance (serum: *p* \< 0.00001, *I*^2^ = 100%; BAL: *p* \< 0.00001, *I*^2^ = 100%) ([Figure 9](#fig9-1753466619866096){ref-type="fig"}).

###### 

Subgroup analysis of TNF-α level in COPD.

![](10.1177_1753466619866096-table4)

  ---------------------------------------------------------------------------------------------------------------------
  Subgroups                    *N*    SMD (95%CI)             *p*              Test of heterogeneity   
  ---------------------------- ------ ----------------------- ---------------- ----------------------- ----------------
  COPD Status                                                                                          

  Stable                       1654   1.33 (0.46--2.21)       *p* = 0.003      98                      *p* \< 0.00001

  Exacerbated                  590    2.43 (0.29--4.57)       *p* = 0.03       99                      *p* \< 0.00001

  FEV1 %                                                                                               

  \>50%                        1046   1.49 (0.88--2.10)       *p* \< 0.00001   94                      *p* \< 0.00001

  \<50%                        4154   1.39 (0.56--2.22)       *p* = 0.0010     98                      *p* \< 0.00001

  Current smoking status\      \      \                       \                \                       \
  Ex-smokers/current smokers   2352   1.63 (0.77--2.49)       *p* = 0.0002     98                      *p* \< 0.00001

  No                           98     0.70 (--1.36 to 2.76)   *p* = 0.51       95                      *p* \< 0.00001

  Country                                                                                              

  Europe                       4461   1.58 (0.94--2.23)       *p* \< 0.00001   98                      *p* \< 0.00001

  Others                       1190   1.76 (0.78--2.74)       *p* = 0.0004     98                      *p* \< 0.00001

  Mean age                                                                                             

  \>60                         1585   0.98 (0.29--1.68)       *p* = 0.006      97                      *p* \< 0.00001

  \<60                         157    0.58 (--0.59 to 1.74)   *p* = 0.33       91                      *p* \< 0.00001

  BMI                                                                                                  

  \>20                         2146   0.72 (0.69--0.76)       *p* \< 0.00001   100                     *p* \< 0.00001

  \<20                         228    2.61 (1.67--3.55)       *p* \< 0.00001   95                      *p* \< 0.00001
  ---------------------------------------------------------------------------------------------------------------------

BMI, Body mass index; COPD, chronic obstructive pulmonary disease; FEV1, first second of forced expiration; TNF-α, tumor necrosis factor-alpha

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to first second of forced expiration (%).](10.1177_1753466619866096-fig3){#fig3-1753466619866096}

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to smoking status.](10.1177_1753466619866096-fig4){#fig4-1753466619866096}

![Subgroup analyses of the relationship between TNF-α and chronic obstructive pulmonary disease (COPD) according to COPD status.](10.1177_1753466619866096-fig5){#fig5-1753466619866096}

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to age.](10.1177_1753466619866096-fig6){#fig6-1753466619866096}

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to country.](10.1177_1753466619866096-fig7){#fig7-1753466619866096}

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to body mass index.](10.1177_1753466619866096-fig8){#fig8-1753466619866096}

![Subgroup analyses of the relationship between tumor necrosis factor-α and chronic obstructive pulmonary disease according to sample source.](10.1177_1753466619866096-fig9){#fig9-1753466619866096}

Meta-regression analysis {#section16-1753466619866096}
------------------------

To further determine the source of heterogeneity, meta-regression analyses were conducted. The results indicated that publication year, region, BMI, NOS, study sample size, and smoking status were not potential sources of heterogeneity ([Table 5](#table5-1753466619866096){ref-type="table"}).

###### 

Meta-regression analysis coefficients for TNF-α levels.

![](10.1177_1753466619866096-table5)

  Covariates       Coefficient   *p*     95% confidence interval
  ---------------- ------------- ------- -------------------------
  Year             −0.44053      0.593   (--0.21028 to 0.12217)
  Region           −0.20124      0.843   (--2.25307 to 1.85058)
  BMI              −0.33315      0.724   (--2.23490 to 1.56859)
  Sample size      −0.000526     0.659   (--0.00293 to 0.00187)
  Smoking status   −0.203374     0.810   (--1.91399 to 1.50724)
  NOS              0.556458      0.886   (--7245434 to 0.83583)

BMI, Body mass index; NOS, Newcastle-Ottawa Quality Assessment Scale; TNF-α, tumor necrosis factor-alpha

Sensitivity analysis and publication bias {#section17-1753466619866096}
-----------------------------------------

The sensitivity analysis showed that removing each of the 40 included studies did not result in significant change in the pooled effect size, indicating that the results of the present meta-analysis were stable ([Table 6](#table6-1753466619866096){ref-type="table"}). Potential publication bias in this meta-analysis was evaluated with a funnel plot. The result showed that the included studies were symmetrically distributed, excluding the presence of significant publication bias ([Figure 10](#fig10-1753466619866096){ref-type="fig"}).

###### 

Sensitivity analysis.

![](10.1177_1753466619866096-table6)

  Study                                               SMD (95% CI)        *p* Heterogeneity   *I* ^2^
  --------------------------------------------------- ------------------- ------------------- ---------
  Calikoglu 2004^[@bibr9-1753466619866096]^           0.69 (0.62--0.76)   *p *\< 0.00001      97
  Agusti 2012^[@bibr10-1753466619866096]^             1.00 (0.91--1.08)   *p *\< 0.00001      97
  Once 2010^[@bibr11-1753466619866096]^               0.70 (0.63--0.77)   *p *\< 0.00001      98
  Kleniewska 2016^[@bibr12-1753466619866096]^         0.70 (0.63--0.77)   *p *\< 0.00001      98
  Rovina 2007^[@bibr13-1753466619866096]^             0.69 (0.62--0.77)   *p *\< 0.00001      97
  Gagnon 2014^[@bibr14-1753466619866096]^             0.71 (0.64--0.79)   *p *\< 0.00001      98
  Ben Anes 2017^[@bibr15-1753466619866096]^           0.72 (0.64--0.79)   *p *\< 0.00001      98
  Perez-de-Liano 2017^[@bibr16-1753466619866096]^     0.68 (0.61--0.75)   *p *\< 0.00001      97
  Foschino Barbaro 2007^[@bibr17-1753466619866096]^   0.69 (0.62--0.77)   *p *\< 0.00001      97
  Barreiro 2013^[@bibr18-1753466619866096]^           0.71 (0.64--0.78)   *p *\< 0.00001      98
  Beeh 2003^[@bibr19-1753466619866096]^               0.71 (0.63--0.78)   *p *\< 0.00001      98
  Di Stefano 2018^[@bibr20-1753466619866096]^         0.71 (0.64--0.78)   *p *\< 0.00001      98
  Breyer 2011^[@bibr21-1753466619866096]^             0.69 (0.62--0.77)   *p *\< 0.00001      98
  Zhang 2016^[@bibr22-1753466619866096]^              0.72 (0.65--0.80)   *p *\< 0.00001      97
  Dima 2010^[@bibr23-1753466619866096]^               0.70 (0.62--0.77)   *p *\< 0.00001      98
  Kawayama 2016^[@bibr24-1753466619866096]^           0.71 (0.63--0.78)   *p *\< 0.00001      98
  Gaki 2011^[@bibr25-1753466619866096]^               0.58 (0.50--0.65)   *p *\< 0.00001      97
  Godoy 2003^[@bibr26-1753466619866096]^              0.71 (0.64--0.78)   *p *\< 0.00001      98
  Hacievliyagil 2012^[@bibr27-1753466619866096]^      0.69 (0.62--0.76)   *p *\< 0.00001      97
  Huertas 2010^[@bibr28-1753466619866096]^            0.69 (0.62--0.76)   *p *\< 0.00001      97
  Ju 2011^[@bibr29-1753466619866096]^                 0.70 (0.63--0.77)   *p *\< 0.00001      98
  Karadag 2007^[@bibr30-1753466619866096]^            0.72 (0.64--0.79)   *p *\< 0.00001      98
  Karadag 2008^[@bibr31-1753466619866096]^            0.72 (0.64--0.79)   *p *\< 0.00001      98
  Shin 2007^[@bibr32-1753466619866096]^               0.71 (0.64--0.79)   *p *\< 0.00001      98
  Kythreotis 2008^[@bibr33-1753466619866096]^         0.69 (0.62--0.76)   *p *\< 0.00001      97
  Liu 2009^[@bibr34-1753466619866096]^                0.69 (0.62--0.76)   *p *\< 0.00001      97
  Huang 20162^[@bibr35-1753466619866096]^             0.68 (0.61--0.75)   *p *\< 0.00001      97
  Moermans 2011^[@bibr36-1753466619866096]^           0.76 (0.69--0.83)   *p *\< 0.00001      97
  Piehl-Aulin 2008^[@bibr37-1753466619866096]^        0.70 (0.62--0.77)   *p *\< 0.00001      98
  Tan 2016^[@bibr38-1753466619866096]^                0.70 (0.63--0.77)   *p *\< 0.00001      97
  Guiot 2017^[@bibr39-1753466619866096]^              0.72 (0.64--0.79)   *p *\< 0.00001      98
  Sarioglu 2015^[@bibr40-1753466619866096]^           0.65 (0.58--0.73)   *p *\< 0.00001      97
  Uzum 2013^[@bibr41-1753466619866096]^               0.71 (0.64--0.79)   *p *\< 0.00001      97
  Kosacka 2015^[@bibr42-1753466619866096]^            0.72 (0.64--0.80)   *p *\< 0.00001      97
  Cheng 2008^[@bibr43-1753466619866096]^              0.59 (0.51--0.67)   *p *\< 0.00001      97
  Valipour 2008^[@bibr44-1753466619866096]^           0.74 (0.64--0.81)   *p *\< 0.00001      97
  Zhang 2010^[@bibr45-1753466619866096]^              0.70 (0.62--0.77)   *p *\< 0.00001      98
  Vera 1996^[@bibr46-1753466619866096]^               1.19 (0.72--1.66)   *p *\< 0.00001      97
  Soler 1999^[@bibr47-1753466619866096]^              1.25 (0.78--1.73)   *p *\< 0.00001      97
  De Godoy 1996^[@bibr48-1753466619866096]^           1.25 (0.78--1.73)   *p *\< 0.00001      97

SMD, Standard mean difference; CI, 95% confidence intervals

![A funnel plot analysis of publication bias.](10.1177_1753466619866096-fig10){#fig10-1753466619866096}

Discussion {#section18-1753466619866096}
==========

COPDs induced by chronic bronchitis and emphysema are characterized by not fully reversible and progressive airflow limitation, and represent one of the most serious public health concerns in the world.^[@bibr49-1753466619866096],[@bibr50-1753466619866096]^ As an inflammatory disease, inflammation of airways and lung parenchyma have been identified as one of the major pathogenic mechanisms of COPD.^[@bibr51-1753466619866096]^ Inflammation is a complex process, in which a variety of cells and molecules are involved and a series of inflammatory signaling pathways are activated.

Previously, several meta-analyses have evaluated the association between TNF-α levels and COPD; however, the conclusions were conflicting. Gan and colleagues performed a meta-analysis including 14 studies and reported a significant correlation between systemic inflammatory markers, including TNF-α, and lung function.^[@bibr52-1753466619866096]^ Bin and colleagues, however, indicated that there was no significant correlation between COPD and TNF-α level in a meta-analysis of 24 studies.^[@bibr53-1753466619866096]^ The main limitation of the previous meta-analyses is the relatively small number of the included studies, which leads to a small size of participant cohort. To overcome this limitation, we conducted the updated meta-analysis presented here, which includes 40 articles with 4152 COPD patients and 1639 healthy controls, to better evaluate the potential associations between TNF-α level and COPD. We found that COPD patients had significantly higher TNF-α levels than healthy controls. To explain this result, the following factors need to be taken into account. First, common genetic or constitutional differences between COPD patients and controls probably exist, and these differences predispose COPD patients to both systemic and pulmonary inflammation.^[@bibr54-1753466619866096]^ Second, during inflammation processes, activated inflammatory cells and a variety of released inflammatory mediators, such as IL-8, IL-6, and TNF-α,can destroy lung structure and promote the inflammatory response of neutrophils.^[@bibr55-1753466619866096]^ Third, the elevated blood inflammatory factors might be explained by several previously proposed mechanisms, such as local pulmonary inflammation due to smoking, oxidative stress, and tissue hypoxia.^[@bibr56-1753466619866096]^

Due to the high heterogeneity, a subgroup analysis was then performed to minimize heterogeneity among the included studies. FEV~1~ is the most widely used parameter for diagnosis and evaluation of treatment effect in severe COPD, and the current COPD staging system is based mainly on this parameter.^[@bibr8-1753466619866096]^ Therefore, we subclassified the patients into two subgroups: FEV~1~% \>50% and FEV~1~% \<50% to perform subgroup analysis. The results showed that TNF-α level was elevated in COPD patients with both FEV~1~% \>50% and FEV~1~% \<50% compared with controls. Smoking is known to be one of the main causes of COPD; thus, a subgroup analysis based on smoking status was performed. We found a significant association between TNF-α level and COPD in participants with smoking history, but we failed to find this association in nonsmoking participants. This result was consistent with that of a study by Mosran and colleagues, who showed that, compared with non-COPD smokers, smokers with COPD had markedly higher levels of TNF-α,^[@bibr57-1753466619866096]^ suggesting that smoking can further increase TNF-α levels. In addition, the level of TNF-α was also associated with COPD status, region of study, and BMI of participants. However, no association was found between TNF-α level and COPD if the mean age was less than 60 years.

Although our results reached the same conclusion as many studies, some other studies report different results. Schmidt-loanas and colleagues suggested there were no significant differences in the correlation between TNF-α levels and COPD exacerbation.^[@bibr58-1753466619866096]^ Monika and colleagues also did not observe any obvious difference in serum TNF-α levels between COPD patients and controls.^[@bibr42-1753466619866096]^ This inconsistency among studies could be explained by differences in study design; different COPD status of enrolled patients across the included studies, since early-stage COPD are insensitive to TNF-α; and the inclusion of studies with different baseline characteristics.

Before we draw any firm conclusions, there are several limitations of this study that need to be considered. First, the significant heterogeneity in the present meta-analysis may limit generalization of the pooled results. Second, the methods for measuring TNF-α level were inconsistent. Third, since we limited the language of publication to English, we may have missed other related studies published in other languages. For example, the literature search for CNKI found several related studies in Chinese, but we excluded them from this study according to the exclusion criteria. Finally, the association between TNF-α level and patient quality of life was not evaluated due to the limited information available.

Conclusion {#section19-1753466619866096}
==========

In this meta-analysis, a significant association between COPD and elevated TNF-α level was identified. These results encourage further exploration of the roles of TNF-α in COPD formation and development, and the potential of TNF-α as a novel biomarker and therapeutic target for COPD.
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